Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma
| Autor: | Kerry Nagee, Carmela Monteiro, Chuhua Zhang, Amir Mohammadi, Zhiqiang Wang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism DNA Mutational Analysis Pancreatic Intraepithelial Neoplasia Acinar Cells medicine.disease_cause Polymerase Chain Reaction Proto-Oncogene Proteins p21(ras) Islets of Langerhans 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Cytology Biopsy Internal Medicine medicine Carcinoma Humans Codon neoplasms Mutation Hepatology medicine.diagnostic_test business.industry medicine.disease digestive system diseases Pancreatic Neoplasms 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer research Pancreatitis KRAS Pancreas business Carcinoma Pancreatic Ductal |
| Zdroj: | Pancreas. 45:337-341 |
| ISSN: | 0885-3177 |
| Popis: | Objectives KRAS mutations are frequent in pancreatic ductal adenocarcinoma, chronic pancreatitis, and mucinous neoplasms. In animal studies, KRAS mutations in acinar and Langerhans islets are associated with pancreatic intraepithelial neoplasia. Clinically, KRAS mutation is sometimes requested on cytology/biopsy specimens and negative results are helpful to rule out pancreatic ductal adenocarcinoma. This study set out to further elucidate these issues. Methods Surgical specimens with pancreatic ductal adenocarcinoma, premalignant lesions, and chronic pancreatitis were reviewed. Tissue microdissections on 53 such areas of 21 cases were performed followed by polymerase chain reaction and pyrosequencing. Results KRAS codon 12 mutations were detected in 100% pancreatic ductal adenocarcinomas. No KRAS codon 12 and 13 mutations were detected in benign acinar and Langerhans islets that lie adjacent to or away from the tumor. Variable mutation frequencies were seen in premalignant lesions. Conclusions The results support such clinical practice that negative KRAS mutation helps rule out pancreatic ductal adenocarcinomas on small cytology/biopsy specimens. Negative KRAS mutations, however, cannot rule out pancreatic premalignant lesions. Additionally, the results that benign pancreas are negative for KRAS mutations complement the findings of other relevant study that KRAS mutation-associated premalignant lesions do not appear to arise from acinar cells or Langerhans islets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|